Knight TherapeuticsKHTRF 71 PB Ratio is 1.20 as of Jul. 08, 2026, which is 48% above its 10-year median of 0.81. GuruFocus rates KHTRF with a GF Score™ of 71/100 and a GF Value™ of $6.16 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 919 Drug Manufacturers companies, Knight Therapeutics ranks better than 67.57% on this metric.
Knight Therapeutics Inc stock PB Ratio (=1.24) is close to 5-year high of 1.24.
The historical rank and industry rank for Knight Therapeutics's PB Ratio or its related term are showing as below:
KHTRF'
s PB Ratio Range Over the Past 10 Years
Min: 0.56 Med: 0.81 Max: 1.64
Current: 1.25
During the past 13 years, Knight Therapeutics's highest PB Ratio was 1.64. The lowest was 0.56. And the median was 0.81.
KHTRF's PB Ratio is ranked better than 67.57% of 919
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs KHTRF: 1.25
During the past 12 months, Knight Therapeutics's average Book Value Per Share Growth Rate was 0.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 2.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 1.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Knight Therapeutics was 9.60% per year. The lowest was -4.50% per year. And the median was 2.70% per year.
Back to Basics: PB Ratio
Knight Therapeutics (OTCPK:KHTRF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Knight Therapeutics PB Ratio Related Terms
Knight Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Knight Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Knight Therapeutics PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Knight Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Knight Therapeutics (KHTRF) has a PB Ratio of 1.20 as of Jul. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Knight Therapeutics and its competitors. This is 48% above median its historical median of 0.81. Over the past decade, Knight Therapeutics' PB Ratio has ranged from 0.56 to 1.64. According to the industry distribution chart, Knight Therapeutics ranks #298 out of 919 companies in the Drug Manufacturers industry, placing it in the top 32.4%.
Is Knight Therapeutics' PB Ratio too high?
Knight Therapeutics' current PB Ratio of 1.20 is 48% above median its 10-year median of 0.81. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 1.64. The Drug Manufacturers industry median PB Ratio is 1.91. Knight Therapeutics' value of 1.20 is 37.2% below this industry median. Based on the distribution chart, Knight Therapeutics ranks #298 out of 919 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Knight Therapeutics has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #298 out of 919 companies for PB Ratio. This puts Knight Therapeutics in the upper half of its industry. The industry median PB Ratio is 1.91. Knight Therapeutics' value of 1.20 is 37.2% below this benchmark. Historically, Knight Therapeutics' own PB Ratio has ranged from 0.56 to 1.64 over the past decade. While the company's 10-year median is 0.81 vs. the industry median of 1.91, Knight Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Knight Therapeutics's current PB Ratio of 1.20 is 37.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Knight Therapeutics and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Knight Therapeutics's current PB Ratio is 1.20, which is 48% above median its own 10-year median of 0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Knight Therapeutics (KHTRF) is currently considered Modestly Overvalued. The stock's GF Value™ is $6.16, compared to a current price of $6.99 — trading 13.5% above its estimated fair value. The current PB Ratio is 1.20, which is 48% above median its 10-year median of 0.81 and 37.2% below the Drug Manufacturers industry median of 1.91. Knight Therapeutics' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Knight Therapeutics (KHTRF), the current PB Ratio is 1.20 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Knight Therapeutics (KHTRF) Overvalued in 2026?
Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued.
The current stock price of $6.99 is trading 13.5% above its estimated GF Value™ of $6.16.
GuruFocus considers Knight Therapeutics to be Modestly Overvalued.
Key valuation signals for KHTRF:
PB Ratio: 1.20 (48% above median its 10-year median of 0.81)
GF Value™: $6.16 vs. price of $6.99 (13.5% above fair value)
Industry Position: 37.2% below the Drug Manufacturers median (#298 of 919)
No single metric tells the full story. See the KHTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
71GF Score
Get the complete analysis for KHTRF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KHTRF has been successfully added to your 
